- 1.
World Health Organization. WHO announces COVID-19 outbreak a pandemic. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic Lest 2.9.2020.
- 2.
Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–3. [PubMed][CrossRef]
- 3.
Folkhälsomyndigheten. Förekomsten av covid-19 i Sverige 21–24 april och 25–28 maj 2020. https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/f/forekomsten-av-covid-19-i-sverige-21-24-april-och-25-28-maj-2020/ Lest 2.9.2020.
- 4.
Pollán M, Pérez-Gómez B, Pastor-Barriuso R et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396: 535–44. [PubMed][CrossRef]
- 5.
Grifoni A, Weiskopf D, Ramirez SI et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020; 181: 1489–1501.e15. [PubMed][CrossRef]
- 6.
Shereen MA, Khan S, Kazmi A et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91–8. [PubMed][CrossRef]
- 7.
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1–23. [PubMed][CrossRef]
- 8.
Christian MD, Poutanen SM, Loutfy MR et al. Severe acute respiratory syndrome. Clin Infect Dis 2004; 38: 1420–7. [PubMed][CrossRef]
- 9.
Chafekar A, Fielding BC. MERS-CoV: Understanding the Latest Human Coronavirus Threat. Viruses 2018; 10: 93. [PubMed][CrossRef]
- 10.
Wu A, Peng Y, Huang B et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020; 27: 325–8. [PubMed][CrossRef]
- 11.
Wang Y, Anirudhan V, Du R et al. RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. J Med Virol 2020; jmv.26264. [PubMed][CrossRef]
- 12.
Hoffmann M, Kleine-Weber H, Schroeder S et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280.e8. [PubMed][CrossRef]
- 13.
Hofmann H, Pyrc K, van der Hoek L et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 2005; 102: 7988–93. [PubMed][CrossRef]
- 14.
Yan R, Zhang Y, Li Y et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367: 1444–8. [PubMed][CrossRef]
- 15.
To KK, Tsang OT, Leung WS et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20: 565–74. [PubMed][CrossRef]
- 16.
Sun B, Feng Y, Mo X et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 2020; 9: 940–8. [PubMed][CrossRef]
- 17.
Peng H, Yang LT, Wang LY et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 2006; 351: 466–75. [PubMed][CrossRef]
- 18.
World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines Lest 28.8.2020.
- 19.
Farrington CP, Miller E. Vaccine trials. Mol Biotechnol 2001; 17: 43–58. [PubMed][CrossRef]
- 20.
Folegatti PM, Bittaye M, Flaxman A et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020; 20: 816–26. [PubMed][CrossRef]
- 21.
van Doremalen N, Lambe T, Spencer A et al. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv 2020; 2020.05.13.093195. [PubMed][CrossRef]
- 22.
Folegatti PM, Ewer KJ, Aley PK et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–78. [PubMed][CrossRef]
- 23.
Wu L, Zhang Z, Gao H et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother 2017; 13: 2078–85. [PubMed][CrossRef]
- 24.
Zhu FC, Li YH, Guan XH et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020; 395: 1845–54. [PubMed][CrossRef]
- 25.
Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205: 7–12. [PubMed][CrossRef]
- 26.
Jackson LA, Anderson EJ, Rouphael NG et al. An mRNA vaccine against SARS-CoV-2 — Preliminary report. N Engl J Med 2020; 383: NEJMoa2022483. [PubMed][CrossRef]
- 27.
Gao Q, Bao L, Mao H et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369: 77–81. [PubMed][CrossRef]
- 28.
Heaton PM. The Covid-19 vaccine-development multiverse. N Engl J Med 2020; 383: NEJMe2025111. [PubMed][CrossRef]
- 29.
Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 2015; 23: 189–95. [PubMed][CrossRef]
- 30.
Huisman W, Martina BEE, Rimmelzwaan GF et al. Vaccine-induced enhancement of viral infections. Vaccine 2009; 27: 505–12. [PubMed][CrossRef]
- 31.
Weiss RC, Scott FW. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immunol Microbiol Infect Dis 1981; 4: 175–89. [PubMed][CrossRef]
- 32.
Coish JM, MacNeil AJ. Out of the frying pan and into the fire? Due diligence warranted for ADE in COVID-19. Microbes Infect 2020; S1286-4579(20)30124-6. [PubMed][CrossRef]
- 33.
Ulrich H, Pillat MM, Tárnok A. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective. Cytometry A 2020; 97: 662–7. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.